Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis

Abstract

Although malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis, successful treatment of haematological malignancies has been rarely reported. We describe the case of a 64-year-old man who presented with non-Hodgkin’s lymphoma (NHL; clinical stage, IVB) concomitant with ESRD. Before chemotherapy, haemodialysis was initiated, and one course of dose-adjusted CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) therapy followed by eight courses of rituximab therapy were administered according to the performance status and degree of organ dysfunction. Consequently, the patient was disease free for 27 months. Thus, rituximab plus CHOP combination therapy was effective for NHL concomitant with ESRD.

Chemotherapy for non‐Hodgkin lymphoma in the hemodialysis patient: A comprehensive review

“…Case reports and case series reporting on actual treatment of NHL patients on HD are shown in Table 1 (rituximab, CVP, and CHOP), 2,3,6,10‐35 Table 2 (various other regimens), 10,19,25,34‐51 and Table 3 (stem cell transplantation), 34,52‐54 and are discussed below. Recommendations on individual drug administrations are summarized in Table 4 3‐5,9‐11,19,25,38,39,43‐46,55‐60 .…”

Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis

“…Information on CTX dosing in this setting was mainly contained in case reports. [6][7][8] We herein present the cases at our institution that required consideration of dose adjustment in this highly susceptible group of patients, and present our approach and results.…”